Abgenix, Amgen, Dyax deal

ABGX and AMGN extended a 1999 deal under which ABGX is using its XenoMouse technology to develop human monoclonal antibodies to undisclosed AMGN antigens. ABGX will receive research payments, and could receive milestone and license payments under the five-year collaboration, plus royalties.

Separately, ABGX and DYAX will combine ABGX’s XenoMouse technology with DYAX’s phage display technology to develop libraries of XenoMouse-derived antibodies for multiple therapeutic targets. The companies will share costs equally, and each has ...